EMAS Conference Highlights

September 19, 2006
Martin Birkhauser, MD
Martin Birkhauser, MD

OBGYN.net Conference CoverageFrom the European Menopause and Andropause Society (EMAS) 5th Congress, Copenhagen, Denmark-July, 2000

OBGYN.net:  “Please tell us what some of the highlights of this Conference are.”

Dr. Martin Birkhauser:  “We had discussions about breast cancer with HRT which is a very important subject and then long term substitution and safety - when to give long term substitution and when not, and the low dose regiments one aspect was including new molecules such as tibolone.”

OBGYN.net:  “Can you tell us something about the results regarding estrogens and breast cancer?”

Dr. Martin Birkhauser:  “The discussion is not yet closed, we’re in the middle of discussions but there has been a confirmation that the risks show a slight increase with HRT but only for the diagnosis not for mortality and that eventually progestins might increase the risk but these discussions are not closed.”

OBGYN.net:  “Can you tell us when and where the next Conference will be?”

Dr. Martin Birkhauser:  “The next Congress will be in three years in the year 2003, and it will be in Israel in Jerusalem.”

OBGYN.net:  “That’s a long time, a lot can happen in three years.  Will there be other Conferences in between about this theme?”

Dr. Martin Birkhauser:  “Yes, of course.  We’ll have the next Amsterdam meeting next year and then we will organize local meetings that are designed to be concentrated on education.  In fact, I think that is an important task especially in comparison to having been less lucky as the west European countries.”

OBGYN.net:  “Are there many European participants in this Conference?”

Dr. Martin Birkhauser:  “We had more than 4,200 participants and most of them were from Europe but overall we had 72 countries represented.”

OBGYN.net:  “Thank you.”